Alps Advisors Inc. raised its stake in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 11.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,351 shares of the biopharmaceutical company’s stock after buying an additional 3,027 shares during the quarter. Alps Advisors Inc. owned approximately 0.10% of Revance Therapeutics worth $836,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Legal & General Group Plc grew its holdings in Revance Therapeutics by 8.1% in the 2nd quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 438 shares in the last quarter. Bank of America Corp DE grew its holdings in Revance Therapeutics by 29.5% in the 1st quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock valued at $151,000 after buying an additional 1,651 shares in the last quarter. Trexquant Investment LP purchased a new stake in Revance Therapeutics in the 2nd quarter valued at $231,000. Voya Investment Management LLC purchased a new stake in Revance Therapeutics in the 2nd quarter valued at $274,000. Finally, American International Group Inc. grew its holdings in Revance Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 12,590 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 834 shares in the last quarter. Institutional investors own 88.70% of the company’s stock.

Several brokerages have issued reports on RVNC. Piper Jaffray Companies restated a “buy” rating and issued a $28.00 target price on shares of Revance Therapeutics in a report on Friday, October 27th. Cantor Fitzgerald set a $50.00 price target on Revance Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 24th. Finally, Zacks Investment Research lowered Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Revance Therapeutics has an average rating of “Buy” and an average price target of $35.20.

WARNING: “Alps Advisors Inc. Has $836,000 Holdings in Revance Therapeutics, Inc. (RVNC)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/14/alps-advisors-inc-has-836000-holdings-in-revance-therapeutics-inc-rvnc.html.

In other Revance Therapeutics news, CFO Lauren P. Silvernail sold 10,000 shares of the stock in a transaction dated Tuesday, November 7th. The stock was sold at an average price of $26.83, for a total value of $268,300.00. Following the sale, the chief financial officer now owns 59,006 shares of the company’s stock, valued at approximately $1,583,130.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark J. Foley purchased 20,000 shares of Revance Therapeutics stock in a transaction on Tuesday, November 7th. The stock was bought at an average cost of $26.96 per share, for a total transaction of $539,200.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $161,760. The disclosure for this purchase can be found here. Insiders sold a total of 59,226 shares of company stock worth $1,464,618 in the last ninety days. 18.86% of the stock is owned by corporate insiders.

Revance Therapeutics, Inc. (RVNC) opened at $26.30 on Tuesday. Revance Therapeutics, Inc. has a 12 month low of $15.85 and a 12 month high of $28.75.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative return on equity of 67.85% and a negative net margin of 37,161.00%. The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.05 million. During the same period in the previous year, the company posted ($0.64) EPS. Revance Therapeutics’s revenue was up .0% on a year-over-year basis. equities research analysts anticipate that Revance Therapeutics, Inc. will post -3.73 EPS for the current year.

Revance Therapeutics Profile

Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Want to see what other hedge funds are holding RVNC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revance Therapeutics, Inc. (NASDAQ:RVNC).

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Stock Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related stocks with our FREE daily email newsletter.